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In the context of cancer immunotherapy, agents that target the immune system to
cancer cells need to fulﬁl two criteria: 1) that they are only expressed on the
desired target cell and 2) that they can elicit a potent immunological response.
Cancer Testis Antigens are a large disparate family of factors ordinarily
expressed in the germ-line but aberrantly expressed across multiple types of
cancer. The ability to enforce their expression on tumour cells is an attractive
strategy that could render such cells potent targets of the immune system, but
very little is known about their regulation. We describe the generation of an
mCherry reporter cell line using HCT116 colorectal carcinoma cells that we
anticipate will be useful for screen-based approaches to identify novel regulators
of CTA expression. Discoveries arising from their use could in future be
exploited to enhance tumour cell immunogenicity and improve cancer immuno-
therapy.
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Harnessing the body’s immune system to target and destroy cancer cells holds great
promise in the war on cancer and this strategy has recently been shown to be highly
eﬀective in clinical trials [1]. Cancer vaccines, a type of immunotherapy, involve
exposing the immune system to highly immunogenic, cancer-speciﬁc antigens,
that subsequently activate both the cellular and humoral branches of the immune sys-
tem, resulting in the targeted destruction of diseased tissue. Cancer testis antigens
(CTA) are a large, disparate family of factors ordinarily expressed in the human
germ-line and placenta, with key functions in reproduction and the cell cycle [2].
CTAs were originally identiﬁed by autologous typing and serological analysis of
cDNA expression libraries (SEREX), which involves the use of a patients’ own cyto-
toxic T-lymphocytes (CTLs) and antibodies respectively, to recognise and respond
to antigens produced by their own tumour cells. Originally, 265 unique CTAs clas-
siﬁed into 58 diﬀerent families were identiﬁed [3] but a recent study using
publically-available data from The Cancer Genome Atlas (TCGA) as well as three
separate transcriptomics data sets (The Genotype-Tissue Expression (GTex) Project,
Ilumina Human BodyMap 2.0 and Nanjing University Medical University (NJMU)
RNA-seq Database) suggests the CTA designation might be applicable to many
more factors [4], although it remains unclear whether all of these transcripts can
be translated into protein. Typically, CTAs are only expressed in the testis and
placenta, and if they are detected in other non-diseased tissues, their expression level
is substantially lower than that observed in their native organ.
The testis is an immune-privileged site: the blood-testis barrier combined with the
absence of HLAClass I presentation on the surface of germ cells prevents the immune
system from interacting and recognising CTAs as self during the establishment of cen-
tral tolerance [5]. Therefore, from an immunological perspective, CTAs are essentially
tumour-speciﬁc and hold great promise for cancer vaccines and immunotherapy.
The CTA NUF2 (also known as Cell Division Cycle-Associated Protein 1 CDCA1)
is a highly conserved protein originally identiﬁed in S. cerevisiae and crucial for
normal chromosome segregation [6]. As a component of the kinetochore, it is
required for the formation of stable microtubule-kinetochore attachments, chromo-
some alignment and the spindle checkpoint during mitosis in mammalian cells
[7]. As well as results from TCGA data, NUF2 overexpression has been reported
in a diverse set of cancers including pancreatic [8], gastric and colorectal [9], lung
(both small cell and non-small cell), cholangiocellular, urinary bladder and renal
[10, 11]. The functional importance of NUF2 in cancer is suggested through screen
based studies; an RNAi lethality screen in the Epithelial Ovarian Cancer (EOC) cell
line A1847 and other EOC lines identiﬁed the factor as important for preventing
apoptosis [12]. Analysis of mutations in the PanCancer compendium data set ofon.2018.e00858
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could aﬀect chromosome segregation and result in aneuploidy [13]. Proof of the
immunogenicity and potential utility of enforcing NUF2 expression for therapeutic
purposes comes from a study demonstrating that NUF2 can activate both CD4þ/Th1
and CTLs [14]. HLA-A24(A*24:02) or HLA-A2(A*02:01)-restricted CTL epitopes
were identiﬁed that induced tumour-reactive CTLs but not autoimmunity; these epi-
topes were found to correspond to NUF2 protein. Importantly, long peptides were
identiﬁed that were capable of activating both Th1 and CTLs.
Despite their general expression acrossmultiple types of cancers, an outstanding issue
is that CTA expression is heterogeneous i.e. not all cases of a particular cancer present
with CTA expression, and evenwithin tumors that express or upregulate CTA expres-
sion, expression does not occur uniformly within all cells [15]. Epigenetic mecha-
nisms, particularly 5-methyl cytosine (5mC) found in CG contexts (DNA
methylation), appear to be involved in CTA silencing. The general DNA demethylat-
ing drug, 50-aza-20deoxycytidine (5-AZA-CdR) activates MAGE-A1 expression in
human melanoma cells [16]. Studies in mouse indicate that promoter methylation
arises during preimplantation development [17] and recent studies indicate the impor-
tance of transcription factor binding in driving the loss of DNA methylation marks
around promoter regions [18] whilst its presence can antagonise transcription factor
binding [19]. These observations are consistent with a model whereby transcription
factors play a dominant role in activating CTA expression, followed by the loss of
DNA methylation that may assist in maintaining gene activation.
Forward based screens, for example using the CRISPR/Cas9 system and single
guide RNAs (sgRNAs), provide a powerful means of identifying novel factors func-
tionally involved in biological processes [20]. How CTAs are correctly regulated re-
mains poorly deﬁned and improvements in our understanding of the basic
mechanisms involved will be crucial in the future development of targeted cell ther-
apies designed to activate their expression in non-expressing cells. Using CRISPR/
Cas gene editing, we describe the generation of a NUF2-mCherry reporter in
HCT116 colorectal carcinoma cells. We propose that these cells will be of utility
in screen-based approaches to identify novel regulators of CTA expression.2. Materials and methods
2.1. NUF2 expression analysis of TCGA and GTex data
Expression data for diﬀerent cancer types analysed was downloaded from The Can-
cer Genome Atlas (TCGA) Research Network (http://cancergenome.nih.gov/). A
custom Perl script extracted expression scores for NUF2 and generated the
median for each type of cancer. For tissue expression data, tissue-ﬁltered box
plots were downloaded from the GTex Portal (https://www.gtexportal.org/home/).on.2018.e00858
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editing
A suitable sgRNA targeting the NUF2 locus close to the STOP codon was designed
using the CHOPCHOP web tool (http://chopchop.cbu.uib.no/index.php) [21, 22]. A
replacement cassette containing the mCherry coding DNA sequence (CDS) lacking
both a start ATG and stop codon, ﬂanked by 500bp homology arms either side of the
Cas9 cut site was generated by Gibson Assembly of gene blocks (IDT) into pJET1.2
cloning vector (Thermo Fisher Scientiﬁc). To prevent hCas9-mediated restriction
following incorporation of the mCherry CDS by Homology Dependent Repair
(HDR), a silent mutation was incorporated into the replacement cassette that elimi-
nated the Protospacer Adjacent Motif (PAM) sequence, changing the sequence from
AGG to AGA, which retained coding for arginine. Following sequencing to conﬁrm
correct assembly into pJET1.2, the replacement cassette was liberated by restriction
digestion of BamHI sites engineered at the ends of the homology arms and the DNA
was used for transfection of HCT116 colorectal carcinoma cells [23].2.3. HCT116 cell culture
Cells were cultured in HCT116 cell media which consisted of Dulbecco modiﬁed
Eagle medium (DMEM) supplemented with 100 IU/ml penicillin and 10% fetal
bovine serum. Cell counting was performed using MuseTM Count & Viability Kit
(Millipore) on a MuseTM Cell Analyzer (Millipore).2.4. qRT-PCR analysis of NUF2 expression
For HCT116 cells, RNA was extracted using Trizol reagent (Thermo Fisher Scien-
tiﬁc). For human lung, RNA was prepared using AllPrep RNA/Protein Kit (Qiagen).
Human Testis total RNA was purchased from Clonetech. Except for lung RNA,
RNAs were additionally treated with Turbo DNase (Thermo Fisher Scientiﬁc). First
strand cDNA was generated using Maxima Reverse Transcriptase (Thermo Fisher
Scientiﬁc) and oligo(dT)18 primers according to the manufacturer’s protocol. cDNAs
were diluted 1:10 and used for qRT-PCR using the Roche Universal Probe Library
System (Roche). Primers compatible with hydrolysis Probe 8 were used and
GAPDH probe and primer set used as the reference gene control. Reactions were
run on a LightCycler 480 II (Roche).2.5. Transfection of HCT116 cells
The day before transfection, 2.5  105 cells were seeded onto the well of a 24 well
plate. On the day of transfection, cells were transfected using Fugene 6 transfection
reagent (Promega) according to the manufacturer’s protocol. Per transfection, a total
of 1 mg of DNA was used. This consisted of hCas9 plasmid (400 ng) [24], a syntheticon.2018.e00858
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containing replacement cassette (200 ng) and a synthetic gRNA expression cassette
containing HRPT gRNA (100 ng). The latter was included to enrich for transfected
cells by culture in 6-Thioguanine (6-TG) containing media. Synthetic gRNA expres-
sion cassettes were designed as described by Mali and colleagues [24]. 16 to 18
hours post transfection, cells were harvested, counted and seeded onto four 15 cm
plates (2  105 cells/plate). Three days after seeding, media was replaced with 6-
TG containing media (ﬁnal concentration, 10 mg/ml). Fresh 6-TG containing media
was replaced every four days. Twelve days after initial transfection, individual col-
onies were identiﬁed by eye, picked and cultured in ﬂat-bottom 96-well plates. Cells
were expanded for DNA preparation and continued culture.2.6. PCR screening and sequencing
Genomic DNA from conﬂuent 96 well plates was prepared using Quick-DNATM 96
Kit (Zymo Research) according to the manufacturer’s protocol. PCR was performed
using KAPA2G Robust HotStart PCR Kit (Kapa Biosystems) according to the man-
ufacturer’s protocol with the inclusion of Enhancer reagent. For the generation of
amplicons for Sanger sequencing, PCR was optimised using Phusion High-
Fidelity DNA Polymerase (Thermo Fisher Scientiﬁc) and gel resolved amplicons pu-
riﬁed using MinElute Gel Extraction Kit (Qiagen) according to the manufacturer’s
protocol.2.7. Sequences
For screening/genotyping PCRs, the following primers were used (listed 50 to 30):
NUF2_50_F1 (agcacatccatataggcttgaa), NUF2_WT_R1 (gccagttgcatcaatgaaga),
NUF2_50_R1 (acatgaactgaggggacagg), NUF2_30_F1 (gaccacctacaaggccaaga),
NUF2_30_R1 (tacctggagcttccatgacc). The sgRNA sequences used for targeting hCas9
were: NUF2_gRNA14 (CGGTATTGAAAAGGCAGCAGAGG), HPRT_gRNA
(aaagtaattcacttacagtctgg). ForNUF2qRT-PCR, the primers usedwere:NUF2_8_F (cca-
gacaagaagtggtggaga) and NUF2_8_R (tgatataactgcacttccaactgac).2.8. Antibodies
The following antibodies were used at the dilutions indicated: Anti-Tubulin
(1:10,000, T6199, Sigma-Aldrich), Anti-RFP (1:700, 6G9, Chromotek) and Anti-
NUF2 (1:100, sc-271-251, Santa Cruz).2.9. Western blot
Pelleted cells (fresh or snap-frozen) were lysed in RIPA buﬀer (1 PBS, 1 % NP40,
0.5% Sodium Doxycholate, 0.1% SDS). Samples were quantiﬁed using Bio-Radon.2018.e00858
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SDS-PAGE gels. Following separation by electrophoresis, proteins were transferred
onto Nitrocellulose membrane (GE Healthcare), blocked in PBST (1  PBS þ 0.1%
Tween-20) þ 5% milk for one hour before incubating with primary antibodies for
two hours. Membranes were washed in PBST, incubated with secondary antibody,
washed in PBST, before HRP signal development using Luminata Forte Western
HRP Substrate (Millipore). For anti-NUF2 antibody, TBS was used instead of
PBS. Signals were detected by exposure of membranes onto Hyperﬁlm ECL
(Amersham).2.10. FACS analysis
Cultured HCT116 and NUF2mCherry/mCherry cells were harvested in 0.25% trypsin
and re-suspended in 1  Dulbecco’s PBS. Two volumes of 100% ice-cold ethanol
were added for ﬁxation and cells were incubated overnight at 20 C. The next
day, cells were washed in 1  PBS and re-suspended in FACS buﬀer (1  PBS,
1  BSA and 10 mg/ml RNase A). Cells were incubated on ice for 15 minutes
with 5 mMDRAQ5TM Fluorescent Probe Solution (Thermo Fisher Scientiﬁc) before
acquisition on a BD LSRFortessa X-20 (BD Biosciences) ﬂow cytometer. Analysis
was performed using FlowJo software (FlowJo).2.11. Cell cycle and viability analysis
Cultured HCT116 and NUF2mCherry/mCherry cells were harvested and labelled using
MuseTM Cell Cycle and Annexin V & Dead Cell Kit (Millipore) according to the
manufacturer’s protocol before running on the corresponding setting on a MuseTM
Cell Analyzer (Millipore).2.12. Cell imaging
Images of live cells in culture were acquired on a Zeiss Axio Observer Z1 (Carl
Zeiss) microscope. For confocal imaging, cells were harvested, ﬁxed in 2% PFA
and seeded by centrifugation (800 rpm, 4 minutes) onto coated slides using a Shan-
don Cytospin (Thermo Fisher Scientiﬁc). After brieﬂy washing with 1 PBS, VEC-
TASHIELD Antifade Mounting Medium with DAPI (Vectorlabs) was applied and
slides covered with cover slips. Images were acquired on an LSM 880 with Aryscan
microscope (Zeiss).3. Results and discussion
Analysis of The Cancer Genome Atlas (TCGA) data revealed that the CTA NUF2 is
consistently over-expressed across a broad range of diﬀerent cancer types (Fig. 1A).on.2018.e00858
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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normal colon has low levels of NUF2 expression, similar to that observed in normal
lung (Fig. 1B). qRT-PCR conﬁrmed that whilst NUF2 expression is undetectable in
non-germ line tissue (in this case lung), it is 2-3 orders of magnitude higher in both
testis and the colorectal carcinoma cell line, HCT116 (Fig. 1C). To generate a re-
porter cell line as a tool for screen-based approaches to identify novel regulators
of NUF2 expression, we used CRISPR/Cas editing to introduce an mCherry CDS
into the endogenous NUF2 locus of HCT116 colorectal carcinoma cells to generate
an in-frame fusion protein. As this gene has a promoter-associated CpG island that
may be involved in regulating its expression, the mCherry CDS was added to the C-
terminus, immediately before the endogenous STOP codon in exon 14 (Fig. 1D).
CHOPCHOP web tool was used to identify a suitable sgRNA sequence, close to
the STOP codon. To enrich for successfully targeted cells, an sgRNA targeting
the HPRT locus which has previously been used in HCT116 cells was also included
[25]. Two separate transfections were performed and a total of 576 colonies were
picked and screened by PCR, initially using primers to detect the mCherry CDS.
13 clones were found to carry themCherry reporter and were expanded up for further
analysis. Using the primers indicated in Fig. 1C and D, which are external to the re-
gions used for the homology arms, PCR on DNA extracted from one clone (P1_E2)
generated amplicons at the expected sizes following successful targeting (Fig. 1E
and Supplemental Fig. S1). PCR using primers 50F þ WTR, designed to detect
the wildtype untargeted allele failed to generate an amplicon at the expected size
indicating these cells are homozygous for insertion of the mCherry reporter; these
cells are hereafter referred to as NUF2mCherry/mCherry(mC/mC).
The strategy of using an mCherry CDS lacking various elements necessary for suc-
cessful transcription (i.e. promoter, start ATG, stop codon, polyadenylation signal)
was to ensure that mCherry expression would only be detected following correct
insertion into the NUF2 locus in the manner anticipated. Expression of NUF2-
mCherry fusion protein was conﬁrmed using several approaches. Western blot anal-
ysis was performed on whole cell extracts/RIPA lysates using both anti-RFP and
anti-NUF2 antibodies. NUF2 protein is predicted to be approximately 54 kDa; the
inclusion of mCherry generates an approximately 80kDa protein and an immunoblot
signal was observed at this size in mC/mC cells (Fig. 2A and Supplemental Fig. S2).
This result was recapitulated when lysates were probed with anti-NUF2 antibody. In
addition to the fact that the size of the band is increased in mC/mC cells, we note the
presence of a non-speciﬁc band approximately 60kDa in size (Fig. 2A, *) present in
both the untargeted parental HCT116 and mC/mC cells. Analysis of live cells by
ﬂuorescence microscopy indicated robust mCherry expression (Fig. 2B). NUF2 is
known to have a major function during metaphase to ensure microtubules correctly
attach to kinetochores. We further examined the subcellular localisation of NUF2-
mCherry protein by confocal microscopy (Fig. 2C). In interphase cells, NUF2-on.2018.e00858
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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Fig. 1. Generation ofNUF2mCherry/mCherry reporter cell line inHCT116 cells. (A)HeatmapofmedianNUF2
expression scores in normal and primary tumour tissues in the following diﬀerent cancers: breast invasive
carcinoma (BRCA); bladder urothelial carcinoma (BLCA); cholangiocarcinoma (CHOL); colon adenocar-
cinoma (COAD); head & neck squamous cell carcinoma (HNSC); kidney chromophobe (KICH); kidney
renal clear cell carcinoma (KIRC); kidney renal papillary cell carcinoma (KIRP); liver hepatocellular carci-
noma (LIHC); lung adenocarcinoma (LUAD); lung squamous cell carcinoma (LUSC); mesothelioma
(MESO); prostate adenocarcinoma (PRAD); rectum adenocarcinoma (READ); thyroid carcinoma
(THCA); uterine corpus endometrioid carcinoma (UCEC); (B). Box plots showing RNA-seq data of
NUF2 expression in diﬀerent tissues indicated. Log10 expression level measured as Transcripts Per Million
(TPM). Lines indicate median and 25th and 75th percentiles. Values shown for each tissue are median and
sample size, respectively: Colon (sigmoid) (0.386, 233); Colon (transverse) (1.933, 274); Lung (1.045,
427) and Testis (44.18, 259). Data obtained from the GTex Portal (https://www.gtexportal.org/home/);
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Fig. 2. Characterisation ofNUF2-mCherry expression. (A)Western blot using antibodies indicated onRIPA
lysates from parental untargetedHCT116 cells as well asNUF2mCherry/mCherry cells. For anti-NUF2 antibody,
a non-speciﬁc band was observed, as indicated by *. Anti-Tubulin antibody signal used as a loading control;
(B) Micrograph images showing ﬂuorescence signal from live HCT116 and NUF2mCherry/mCherry cells;
(C) Confocal micrograph images showing ﬂuorescence signals inNUF2mCherry/mCherry cells. Nuclei were re-
vealed using DAPI stain and used to distinguish interphase from mitotic cells.
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observed. The cytoplasmic nature of the protein agrees with previous observations
in both human A341 epidermoid carcinoma and HEK 293 cells (https://www.
proteinatlas.org/ENSG00000143228-NUF2/cell#human). In mitotic cells, NUF2-
mCherry distribution became more punctate and co-localised with chromosomal re-
gions most likely to be centromeres, at stages indicative of metaphase and anaphase.(C) Bar graphs showing relative, GAPDH-normalised qRT-PCR expression levels of NUF2 in HCT116
cells. Log10 expression levels in human lung and testis are shown as controls (negative and positive, respec-
tively). Expression is shown relative to levels in lung; (D)Diagram showingCRISPR/Cas gene editing strat-
egy used. Sequence of sgRNAused to target hCas9 to theNUF2 locus is shown. Primers used in targeting the
NUF2 locus are located outside the homology arms; (E) PCR results of targeted NUF2mCherry/mCherry clones
(labelled mC/mC). Table shows expected amplicon sizes using primers indicated in D. Images of gel
resolved amplicons using the primer combinations indicated stained with ethidium bromide and visualised
under UV light.
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GFP-tagged NUF2 protein in DT40 cells [26], and suggest that NUF2-mcherry pro-
tein is capable of correct localisation during the cell cycle.
We next assessed the ability to detect NUF2-mCherry signal by FACS. The mCherry
expression proﬁle for mC/mC cells, was shifted relative to signal observed in
parental, untargeted HCT116 cells (Fig. 3A). Cell cycle analysis of live-gated cells
using a ﬂuorescent DNA dye (DRAQ5TM) revealed that mCherry is expressed
throughout the cell cycle (Fig. 3B), consistent with our immunoﬂuorescence data.
Quantitative analysis of the percentage of cells at diﬀerent stages of the cell cycle
revealed a signiﬁcant increase in cells in both G1 and S phase with a concomitant
reduction in the proportion in G2/M phase (Fig. 3C). Combined with our microscopy
data, this suggests that although NUF2-mCherry correctly localises during mitosis,
the presence of the mCherry moiety may be aﬀecting NUF2 function. The human
genome reportedly encodes twenty cyclin dependent kinases (CDKs) and twenty-
nine cyclins (CLNs) [27]. While we cannot formally exclude any direct eﬀect on
the levels of the various cyclin proteins expressed throughout the cell cycle, correct
NUF2 function is known to be required for the formation of stable microtuble-
kinetochore attachments and subsequent passage through the mitotic spindle check-
point. As these processes are regulated by Cyclin A proteins [28], we consider these
to be candidate cyclins whose expression is perturbed by the presence of the
mCherry moiety on NUF2 protein. Despite this eﬀect on the cell cycle, this did
not translate to any signiﬁcant eﬀect on cell viability (Figs. 3D and E).
The successful exploitation of CTAs for use in cancer vaccines requires improve-
ments in our understanding of how these factors are regulated. Mammalian gameto-
genesis, particularly spermatogenesis is a highly controlled process and there is
likely to be co-ordinate regulation of these factors. Presently, little is known about
how NUF2 expression is regulated at the transcriptional level. A single, previous
study in HCT116 cells claimed that the highly abundant protein heterogeneous nu-
clear ribonucleoprotein K (HNRNPK) is an important transcriptional activator of
NUF2 [29]. Despite a number of attempts, we have been unable to generate
HNRNPK-deﬁcient cells in order to both validate the role of HNRNPK in regulating
NUF2 expression as well as to serve as a positive control in order to test our cell line.
However, we anticipate that the cell line described in this present study will serve as
a useful tool in future screen-based approaches designed to identify novel regulators
of NUF2 expression.
We note that these labelled cells could also be suitable for tracking purposes in pre-
clinical mouse models of colorectal cancer. HCT116 and other colorectal cancer cell
lines have been successfully used in a number of transplantation models involving
immunodeﬁcient mice, using both subcutaneous and orthotopic xenografts [30].
Labelling studies have also been performed involving the transduction of colorectalon.2018.e00858
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 3. Characterisation of NUF2-mCherry cell line proliferation and viability. (A) FACS scatter plot of
HCT116 cells overlaid with NUF2mCherry/mCherry cells. Numbers are percentages of live and single-gated
events within gates indicated; (B) Histograms showing DRAQ5TM staining proﬁle of cell lines indicated.
Populations divided into G1, S and G2/M. Numbers indicate percentage of live-gated cells; (C) Bar
graphs showing percentage of cells at diﬀerent cell cycle stages indicated. Exact p-values (n ¼ 6,
Mann-Whitney) are 0.0152 (G0/G1), 0.0043 (S) and 0.0022 (G2/M); (D) FACS plots of quadrant-
gated HCT116 cells labelled with MuseTM Annexin & Dead Cell Assay reagent for viability analysis.
Quadrants indicated are live, early apoptotic, late apoptotic and dead; (E) Bar graphs showing percentage
of cells in the diﬀerent viability groups indicated. Exact p-values (n ¼ 6, Mann-Whitney) are 0.9372
(live), 0.9372 (early apoptotic), 0.9372 (late apoptotic) and >0.999 (total apoptotic).
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clonal populations of such cells [31, 32], which are likely to have variable reporter
expression. The fact that the reporter cell line we have generated carries the mCherry
reporter fused to an endogenous gene, controlled by its endogenous regulatory ele-
ments indicates more physiological and more importantly, stable regulation of re-
porter expression. This would be an important and useful feature for longitudinal
studies. As mCherry ﬂuorescence from these cells is readily detectable by FACs,
these cells would be useful in monitoring and quantifying the spread of tumour
growth both within organs and possibly by metastasis. They could therefore serve
as a tool for preclinical studies testing the eﬀectiveness of diﬀerent therapeutic stra-
tegies. Finally, the presence of the mCherry moiety fused to NUF2 could be utilisedon.2018.e00858
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tigate mammalian mitosis.Declarations
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